Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
carboplatin (paraplatin) (1 trial)
pemetrexed (alimta) (1 trial)
nimotuzumab (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Glioma (Phase 2)
Trials (2 total)
Trial APIs (3 total)